15-year-old experience in conducting pharmacogenetic studies: results and prospects

Abstract

Currently, the clinical pharmacogenetics is a promising technology for personalized medicine, allowing individualizing the approach to the assessment of risk factors for development of disease, their prevention and treatment with the use of medicines. Individual pharmacological response to drugs is determined by single nucleotide polymorphisms (SNP) in the genes encoding proteins participating in the biotransformation of drugs in the human body. We studied the role of polymorphic marker of CYP2C9*3 in the re sponse to warfarin, CYP2C9 gene polymorphism in the development of NAIGP-gastropathy, allelic variant CYP2D6*4 in deceleration of biotransformation tricyclic antidepressants; CYP2C19*2 reduced effectiveness of clopidogrel, the role of polymorphism SLCO1B1*5 in the frequency adverse reaction of statins, etc. We also displayed ethnic characteristics of the distribution of allelic variants of genes. The proposed module "Pharmacogenetics" in the framework of the implementation of computerized systems for decision support. Thus, pharmacogenetic testing is a promising tool for personalized medicine, prepared for active introduction into clinical practice with the aim of improving the efficiency and safety of drug therapy.